Higher serum urate concentration is associated with decreased risk of Parkinson's disease (PD) as well as slower disease progression, but its relationship with severity of PD remains unclear. This study investigated whether changes in serum urate concentration over 5 years were associated with disease progression assessed by MDS-UPDRS Part III score, Hoehn and Yahr stage, or DaTscan imaging. Average serum urate concentration was stable over time and change in serum urate concentration did not correlate with worsening of measures of PD progression. These results suggest that serum urate concentration is not a monitoring biomarker of PD progression in early stages.
Keywords: Parkinson’s disease; disease progression; longitudinal study; urate.
Conflict of interest statement
EAM served as a Data and Safety Monitoring Board (DSMB) member for Novartis Pharmaceuticals and Shire Human Genetic Therapies, served on an advisory committee for Biogen, consulted for Cerevance, Intrance, Inventram, Lavin Consulting, and Myolex, and his institution received grants on his behalf from Amylyx Pharmaceuticals, GlaxoSmithKline, and Mitsubishi Tanabe Pharmaceuticals. MAS served as a DSMB member for Eli Lilly and Company, and served on advisory boards for Denali Therapeutics, nQ Medical, and Prevail Therapeutics. Other authors report no relevant conflicts of interest.